These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 27713145

  • 1. Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma.
    Schneider MA, Muley T, Kahn NC, Warth A, Thomas M, Herth FJ, Dienemann H, Meister M.
    Oncotarget; 2016 Nov 01; 7(44):71285-71297. PubMed ID: 27713145
    [Abstract] [Full Text] [Related]

  • 2. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
    Franceschini MC, Ferro P, Canessa PA, Battolla E, Dessanti P, Valentino A, Casolari L, Fontana V, Pezzi R, Fedeli F, Pistillo MP, Roncella S.
    Anticancer Res; 2014 Dec 01; 34(12):7425-9. PubMed ID: 25503183
    [Abstract] [Full Text] [Related]

  • 3. Biomarkers for malignant pleural mesothelioma: a meta-analysis.
    Gillezeau CN, van Gerwen M, Ramos J, Liu B, Flores R, Taioli E.
    Carcinogenesis; 2019 Nov 25; 40(11):1320-1331. PubMed ID: 31169881
    [Abstract] [Full Text] [Related]

  • 4. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
    Ferro P, Canessa PA, Battolla E, Dessanti P, Franceschini MC, Chiaffi L, Morabito A, Fontana V, Pezzi R, Fedeli F, Pistillo MP, Roncella S.
    Anticancer Res; 2013 Jun 25; 33(6):2707-13. PubMed ID: 23749930
    [Abstract] [Full Text] [Related]

  • 5. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
    Muley T, Dienemann H, Herth FJ, Thomas M, Meister M, Schneider J.
    J Thorac Oncol; 2013 Jul 25; 8(7):947-51. PubMed ID: 23777840
    [Abstract] [Full Text] [Related]

  • 6. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.
    Burt BM, Lee HS, Lenge De Rosen V, Hamaji M, Groth SS, Wheeler TM, Sugarbaker DJ.
    Ann Thorac Surg; 2017 Nov 25; 104(5):1679-1687. PubMed ID: 28964420
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
    Demir M, Kaya H, Taylan M, Ekinci A, Yılmaz S, Teke F, Sezgi C, Tanrikulu AC, Meteroglu F, Senyigit A.
    Lung; 2016 Jun 25; 194(3):409-17. PubMed ID: 27032653
    [Abstract] [Full Text] [Related]

  • 8. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.
    Cristaudo A, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, Chella A, Lucchi M, Mussi A, Foddis R.
    J Thorac Oncol; 2011 Sep 25; 6(9):1587-93. PubMed ID: 21642872
    [Abstract] [Full Text] [Related]

  • 9. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
    Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T.
    J Thorac Oncol; 2008 Nov 25; 3(11):1317-24. PubMed ID: 18978568
    [Abstract] [Full Text] [Related]

  • 10. Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma.
    Bonotti A, Simonini S, Pantani E, Giusti L, Donadio E, Mazzoni MR, Chella A, Marconi L, Ambrosino N, Lucchi M, Mussi A, Cristaudo A, Foddis R.
    Int J Biol Markers; 2017 Mar 02; 32(1):e126-e131. PubMed ID: 27646775
    [Abstract] [Full Text] [Related]

  • 11. Is soluble mesothelin-related protein an upfront predictive marker of pleural mesothelioma? A prospective study on Italian workers exposed to asbestos.
    Filiberti R, Marroni P, Spigno F, Merlo DF, Mortara V, Caruso P, Cioè A, Michelazzi L, Bruzzone A, Bobbio B, Simonassi C, Del Corso L, Galli R, Racchi O, Dini G, Linares R, Mencoboni M.
    Oncology; 2014 Mar 02; 86(1):33-43. PubMed ID: 24401539
    [Abstract] [Full Text] [Related]

  • 12. Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial.
    Katz SI, Roshkovan L, Berger I, Friedberg JS, Alley EW, Simone CB, Haas AR, Cengel KA, Sterman DH, Albelda SM.
    Lung Cancer; 2021 Apr 02; 154():5-12. PubMed ID: 33561782
    [Abstract] [Full Text] [Related]

  • 13. Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals.
    De Santi C, Pucci P, Bonotti A, Melaiu O, Cipollini M, Silvestri R, Vymetalkova V, Barone E, Paolicchi E, Corrado A, Lepori I, Dell'Anno I, Pellè L, Vodicka P, Mutti L, Foddis R, Cristaudo A, Gemignani F, Landi S.
    Occup Environ Med; 2017 Jun 02; 74(6):456-463. PubMed ID: 28343162
    [Abstract] [Full Text] [Related]

  • 14. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
    Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J.
    Ann Thorac Surg; 2008 Jan 02; 85(1):265-72; discussion 272. PubMed ID: 18154821
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.
    Ak G, Tada Y, Shimada H, Metintas S, Ito M, Hiroshima K, Tagawa M, Metintas M.
    BMC Cancer; 2017 Mar 23; 17(1):212. PubMed ID: 28335760
    [Abstract] [Full Text] [Related]

  • 17. Putative Biomarkers for Malignant Pleural Mesothelioma Suggested by Proteomic Analysis of Cell Secretome.
    Lacerenza S, Ciregia F, Giusti L, Bonotti A, Greco V, Giannaccini G, D'Antongiovanni V, Fallahi P, Pieroni L, Cristaudo A, Lucacchini A, Mazzoni MR, Foddis R.
    Cancer Genomics Proteomics; 2020 Mar 23; 17(3):225-236. PubMed ID: 32345664
    [Abstract] [Full Text] [Related]

  • 18. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
    Guarrera S, Viberti C, Cugliari G, Allione A, Casalone E, Betti M, Ferrante D, Aspesi A, Casadio C, Grosso F, Libener R, Piccolini E, Mirabelli D, Dianzani I, Magnani C, Matullo G.
    J Thorac Oncol; 2019 Mar 23; 14(3):527-539. PubMed ID: 30408567
    [Abstract] [Full Text] [Related]

  • 19. Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report.
    Beije N, Kraan J, den Bakker MA, Maat APWM, van der Leest C, Cornelissen R, Van NM, Martens JWM, Aerts JGJV, Sleijfer S.
    Cell Oncol (Dordr); 2017 Oct 23; 40(5):511-519. PubMed ID: 28577209
    [Abstract] [Full Text] [Related]

  • 20. Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
    Jakubec P, Pelclova D, Smolkova P, Kolek V, Nakladalova M.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep 23; 159(3):472-9. PubMed ID: 24781044
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.